ezutromid   Click here for help

GtoPdb Ligand ID: 11110

Synonyms: 5-ethylsulfonyl-NBO | SMT C1100 | SMTC 1100 | SMTC1100
Compound class: Synthetic organic
Comment: Ezutromid (SMT C1100) is a clinical stage compound that was developed for its ability to increase expression of utrophin (UTRN; P46939), as a substitute for missing the dystrophin (DMD; P11532) in Duchenne muscular dystrophy (DMD) patients [1]. It is orally active. The aryl hydrocarbon receptor (AhR) has been reported as a molecular target for ezutromid, with ezutromid behaving as an AhR antagonist [2]. Ezutromid and other AhR antagonists up-regulate utrophin, adding to the proposition that this pathway offers disease-modifying potential for DMD.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 3
Hydrogen bond donors 0
Rotatable bonds 3
Topological polar surface area 68.55
Molecular weight 337.08
XLogP 4.3
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES CCS(=O)(=O)c1ccc2c(c1)nc(o2)c1ccc2c(c1)cccc2
Isomeric SMILES CCS(=O)(=O)c1ccc2c(c1)nc(o2)c1ccc2c(c1)cccc2
InChI InChI=1S/C19H15NO3S/c1-2-24(21,22)16-9-10-18-17(12-16)20-19(23-18)15-8-7-13-5-3-4-6-14(13)11-15/h3-12H,2H2,1H3
No information available.
Summary of Clinical Use Click here for help
Ezutromid reached Phase 2 proof of concept evaluation for DMD. Despite promising efficacy and evidenece of target engagement at 24 weeks, trial endpoints were not met after 48 weeks and development was terminated. Lack of long-lived efficacy is suggested to be a result of ezutromid's less than ideal physicochemical properties and weak metabolic profile.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02858362 Proof of Concept Study to Assess Activity and Safety of SMT C1100 (Ezutromid) in Boys With Duchenne Muscular Dystrophy (DMD) Phase 2 Interventional Summit Therapeutics